SCHEMBL3763347

SCHEMBL3763347

O=C(NC12CC3CC(CC(C3)C1)C2)OCC(F)(F)Br

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.47
EPHX2 P34913 6/20 0.46
EPHX1 P07099 1/20 0.46
ALDH1A1 P00352 4/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
MAPT P10636 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
LMNA P02545 1/20 0.44
THRB P10828 1/20 0.44
HTT P42858 1/20 0.44
MAPK1 P28482 1/20 0.42
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12994522 0.81 L3MBTL1 (0.44) L3MBTL1EPHX2EPHX1ALDH1A1KMT2A
SCHEMBL14644904 0.78 EPHX2 (0.57) L3MBTL1EPHX2EPHX1ALDH1A1KMT2A
SCHEMBL544446 0.76 CYP17A1 (0.48) ALDH1A1KMT2AMEN1MAPTSMN1; SMN2
SCHEMBL13320026 0.75 LMNA (0.58) L3MBTL1EPHX2EPHX1ALDH1A1KMT2A
SCHEMBL14644923 0.74 L3MBTL1 (0.52) L3MBTL1EPHX2EPHX1ALDH1A1KMT2A
SCHEMBL13320029 0.73 L3MBTL1 (0.58) L3MBTL1EPHX2EPHX1ALDH1A1KMT2A
SCHEMBL29103915 0.73 EPHX2 (0.55) EPHX2EPHX1ALDH1A1KMT2AMEN1
SCHEMBL12994574 0.73 L3MBTL1 (0.48) L3MBTL1EPHX2EPHX1ALDH1A1KMT2A
SCHEMBL13320019 0.72 L3MBTL1 (0.57) L3MBTL1EPHX2EPHX1ALDH1A1KMT2A
SCHEMBL17348282 0.72 L3MBTL1 (0.54) L3MBTL1EPHX2EPHX1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283106-B2 Sulfonic acid salt and derivative thereof, photoacid generator agent, and resist material and pattern formation method using the photoacid generator agent CENTRAL GLASS COMPANY, LIMITED (JP) 2012-10-09 US disclosed
US-8283106-B2 Sulfonic acid salt and derivative thereof, photoacid generator agent, and resist material and pattern formation method using the photoacid generator agent CENTRAL GLASS COMPANY, LIMITED (JP) 2012-10-09 US disclosed
US-8283106-B2 Sulfonic acid salt and derivative thereof, photoacid generator agent, and resist material and pattern formation method using the photoacid generator agent CENTRAL GLASS COMPANY, LIMITED (JP) 2012-10-09 US disclosed
US-20100304303-A1 Novel Sulfonic Acid Salt and Derivative Thereof, Photoacid Generator Agent, and Resist Material and Pattern Formation Method Using the Photoacid Generator Agent CENTRAL GLASS COMPANY, LIMITED (JP) 2010-12-02 US disclosed
US-20100304303-A1 Novel Sulfonic Acid Salt and Derivative Thereof, Photoacid Generator Agent, and Resist Material and Pattern Formation Method Using the Photoacid Generator Agent CENTRAL GLASS COMPANY, LIMITED (JP) 2010-12-02 US disclosed
US-20100304303-A1 Novel Sulfonic Acid Salt and Derivative Thereof, Photoacid Generator Agent, and Resist Material and Pattern Formation Method Using the Photoacid Generator Agent CENTRAL GLASS COMPANY, LIMITED (JP) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100304303-A1 Novel Sulfonic Acid Salt and Derivative Thereof, Photoacid Generator Agent, and Resist Material and Pattern Formation Method Using the Photoacid Generator Agent ARF1, ARF5, ARF6 L3MBTL1 1907/4885EPHX2 1065/4885EPHX1 1728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.